Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

Maartje G. Schouwenburg*, Karijn P. M. Suijkerbuijk, Rutger H. T. Koornstra, Anouk Jochems, Michiel C. T. van Zeijl, Alfons J. M. van den Eertwegh, John B. A. G. Haanen, Maureen J. B. Aarts, Alexander C. J. van Akkooi, Franchette W. P. J. van den Berkmortel, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Wim H. Kruit, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Jacobus J. M. van der Hoeven, Michel W. J. M. Wouters

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number1940
Number of pages11
JournalCancers
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2019

Keywords

  • melanoma
  • metastasis
  • targeted therapy
  • immune checkpoint inhibitors
  • lactate dehydrogenase
  • real-life data
  • prognostic factors
  • METASTATIC MELANOMA
  • LACTATE-DEHYDROGENASE
  • IPILIMUMAB
  • DABRAFENIB
  • PEMBROLIZUMAB
  • NIVOLUMAB
  • OUTCOMES

Cite this